ARCHIVE

• Kirin-do: Double-digit Increases in Sales, Profits
  April 16, 2001

• Criteria for Disclosure, Non-disclosure Published
  April 16, 2001

• MEDICAL DEVICE NEWS IN BRIEF
  April 16, 2001

• Hitachi, Myriad, Oracle, Friedli to Tie Up in Proteomics
  April 16, 2001

• JPA Leader Comments on New Deregulation Promotion Plan
  April 16, 2001

• Sankyo to Be Aggressive in Genomic Drug Discovery: Dr Hiraoka
  April 16, 2001

• Toyama to Exclusively Market YP-14 Jointly Developed with Taiho
  April 16, 2001

• Review of NHI Price System Included in New Deregulation Plan
  April 16, 2001

• Daiichi, Medtronic Codevelop Intrathecal Baclofen Therapy
  April 16, 2001

• Novartis to Double Sales in 5 Years in Transplantation, Immunology, Cancer
  April 16, 2001

• REGULATORY NEWS IN BRIEF -1-
  April 16, 2001

• Kirin Brewery to Survive by Focusing on Cancer, Nephrology, Allergy/Immunology
  April 16, 2001

• The Cues in Pharma Communication (2)
  April 16, 2001

• Quintiles to Double Its Sales in Japan in FY2001
  April 16, 2001

• REGULATORY NEWS IN BRIEF -2-
  April 16, 2001

• Immediate PMS of Mobic Undertaken by Nippon Boehringer Ingelheim, Daiichi
  April 16, 2001

• Bungyo Rate Exceeds 40%for Two Consecutive Months
  April 16, 2001

• Developing Anti-AIDS Vaccine to Be Given Top Priority: Merck Company Foundation
  April 16, 2001

• Reform of Medical Education Proposed to Promote Patient-centered Healthcare
  April 16, 2001

• BUSINESS NEWS IN BRIEF -2-
  April 16, 2001

ページ

• « 先頭
• ‹ Prev
• …
• 762
• 763
• 764
• 765
• 766
• 767
• 768
• 769
• 770
• …
• Next ›
• 最終 »